# Verastem, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Verastem, Inc.).

## Overview

Verastem, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for cancer. Its business centers on oncology drug candidates and approved products, with development, manufacturing, and commercialization activities conducted through third-party partners.

## Products & services

• AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets)
• Oncology drug development and clinical programs
• Regulatory approval and commercialization of cancer therapies
• Third-party manufacturing and supply chain management

- **Commercial oncology therapy** (55%) — Approved cancer treatment sold in the U.S. for a specific oncology indication.
- **Clinical-stage product candidates** (35%) — Drug candidates in development for additional oncology indications and future approvals.
- **Regulatory and commercialization activities** (10%) — Activities tied to approval, launch, market access, and post-approval support.

- AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets)
- Oncology drug development and clinical programs
- Regulatory approval and commercialization of cancer therapies
- Third-party manufacturing and supply chain management

## Customers

Verastem’s direct customers are healthcare providers, hospitals, oncology practices, and specialty pharmacies that prescribe or dispense its cancer therapies. Indirectly, access depends on payors and government reimbursement programs, since coverage and rebate terms influence whether patients can obtain treatment. The company also relies on clinical investigators and research institutions during development of its pipeline.

- **Oncology prescribers** (primary) — Oncologists and cancer centers that prescribe AVMAPKI FAKZYNJA CO-PACK for eligible patients.
- **Specialty pharmacies** (primary) — Dispense the product and manage patient access, fulfillment, and distribution.
- **Government and commercial payors** (primary) — Medicaid, 340B, VA/FSS, and private payors that determine reimbursement and net access.
- **Clinical research sites** (secondary) — Hospitals, investigators, and CRO-supported sites that run trials for pipeline candidates.

- Oncologists and cancer treatment centers prescribing the therapy
- Specialty pharmacies dispensing oncology medicines
- Payors and reimbursement programs influencing patient access
- Clinical investigators and research sites supporting trials

## Geography

Verastem is headquartered in the United States and its commercial focus is primarily the U.S. market. The company also faces foreign-market pricing and reimbursement dynamics typical of global pharmaceutical development, but the disclosed commercial emphasis is domestic. Its operating model depends on third-party manufacturers and research partners, which can be located outside the company’s headquarters.

- Headquartered in the United States
- Primary commercial market is the U.S.
- Subject to U.S. federal and state pricing programs
- Foreign pricing controls can affect future international launches

## Strategy

Verastem’s strategy is centered on building a commercial oncology franchise around AVMAPKI FAKZYNJA CO-PACK while advancing additional product candidates through clinical development. The company also focuses on securing reimbursement, maintaining supply through third-party manufacturers, and expanding the evidence base needed for broader adoption and future approvals.

- **Commercialize AVMAPKI FAKZYNJA CO-PACK** (short-term) — The company’s near-term business depends heavily on uptake of its approved oncology product.
- **Advance clinical pipeline** (medium-term) — Additional approvals are needed to diversify the product base and extend the franchise.
- **Strengthen supply and manufacturing reliability** (medium-term) — Third-party manufacturing is essential to both commercial supply and clinical development.

- Grow adoption of AVMAPKI FAKZYNJA CO-PACK in the U.S.
- Advance pipeline candidates through clinical development
- Secure reimbursement and access across payor channels
- Depend on third-party manufacturing and CRO execution
- Build regulatory and commercial capabilities for oncology launches

## Risks

Verastem is exposed to concentration risk because its business depends heavily on the commercial success of a single approved product and on future pipeline execution. The company also faces typical biotech risks around clinical trial failure, regulatory delays, third-party manufacturing dependence, reimbursement pressure, and financing needs.

- **Dependence on AVMAPKI FAKZYNJA CO-PACK** [high] — A large share of the company’s commercial prospects depends on one approved oncology product.
- **Clinical development failure** [high] — Pipeline candidates may not show sufficient efficacy or safety to gain approval.
- **Third-party manufacturing dependence** [high] — The company has no manufacturing facilities and relies on external suppliers for supply.
- **Reimbursement and pricing pressure** [medium] — Coverage, rebates, and government pricing programs can reduce net revenue and access.
- **Financing and debt servicing risk** [high] — Debt obligations and potential acceleration could constrain operations and development spending.
- **Regulatory and advertising enforcement** [medium] — FDA and other agencies can impose requirements, warnings, or launch restrictions.

- Heavy dependence on AVMAPKI FAKZYNJA CO-PACK sales
- Clinical trial and regulatory approval risk for pipeline assets
- Third-party manufacturing and supply chain disruption risk
- Reimbursement, pricing, and government program pressure
- Debt and financing risk if cash generation is insufficient

## Accounting

Verastem’s reported results are shaped by revenue recognition for pharmaceutical sales, including gross-to-net deductions for rebates, discounts, and chargebacks under government and private payor programs. Investors should also watch estimates for product returns, rebates, contingent liabilities, and debt-related accounting, since these can materially affect revenue, liabilities, and cash flow timing.

- **Revenue recognition and gross-to-net deductions** — Net product revenue
- **Government pricing programs** — Accrued rebates and revenue reserves
- **Product return and rebate reserves** — Revenue and liabilities
- **Debt and revenue participation accounting** — Interest expense, liabilities, and net revenue

- Gross-to-net deductions for rebates, discounts, and chargebacks
- Government pricing programs affect revenue and accrued liabilities
- Product sales returns and rebate estimates require judgment
- Debt and revenue-participation obligations affect liabilities
- Clinical and regulatory costs are expensed as incurred

---

*Last updated: 2026-04-29T05:07:43.304904+00:00*